NCT06413615View on ClinicalTrials.gov

A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

FDA022-BB05

Monoclonal antibody-drug conjugate for injection

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY